Aditxt Inc. to Showcase Adimune Inc.'s Autoimmune Therapeutics Innovations in Upcoming Livestream

Aditxt Inc. (NASDAQ: ADTX) is preparing to host a significant livestream event on July 22, 2025, at 1:00 p.m. ET, focusing on the groundbreaking work of its subsidiary, Adimune Inc., in the field of autoimmune therapeutics. The event will feature Aditxt Co-founder and CEO Amro Albanna, who will discuss Adimune's innovative strategies, upcoming milestones, and the vast potential within the rapidly expanding autoimmune disease market. Hosted by Jack Marks of Wall Street Reporter, the livestream is poised to illuminate Adimune's role in addressing some of the most pressing health challenges through cutting-edge solutions.

The autoimmune disease market is a pivotal area of concentration for Aditxt, as the company aims to utilize its distinctive innovation platform to hasten the development and implementation of health solutions. Aditxt's methodology encompasses a collaborative ecosystem that brings together research institutions, industry partners, and shareholders, all united in their efforts to confront urgent health issues. This livestream presents a unique opportunity for stakeholders and the general public to acquire a deeper understanding of Adimune's advancements and the wider ramifications for the field of autoimmune therapeutics.

Beyond autoimmune diseases, Aditxt is dedicated to fostering innovation across various sectors, including public health and women's health, as part of its strategy to democratize innovation and incorporate diverse perspectives into collective progress. The company's approach ensures autonomy for each program while maintaining alignment with its core mission to discover, develop, and deploy health solutions that tackle some of the most critical challenges in today's healthcare landscape. For more information on Aditxt's initiatives, visit https://www.aditxt.com.